Product Description
CKD-396 is being developed by Chong Kun Dang for the treatment of patients with Type2 Diabetes Mellitus. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04246190?term=CKD-396&draw=2&rank=1)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chong Kun Dang
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| A65_03BE1921 | P1 |
Unknown status |
Type 2 Diabetes |
2020-04-10 |
50% |
2022-01-04 |
Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|